Evaluation of Remnant Cholesterol Levels and Monocyte-to-HDL-cholesterol Ratio as Predictors of Coronary Artery Disease Severity in Patients With Acute Coronary Syndrome

ConditionsAcute Coronary Syndrome ACS (Acute Coronary Syndrome)Monocyte to HDL Cholesterol Ratio STEMI Non STEMI

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-65

SponsorAssiut University

About this trial

1. Evaluation of serum level of remnant cholesterol and monocyte/HDL ratio as predictors of severity of coronary artery disease in patients with acute coronary syndrome. 2. Evaluate predictive value of remnant cholesterol serum level and monocyte/HDL ratio to detect in-hospital worse clinical outcomes and 45 days major adverse cardiac events (MACE) after acute coronary syndrome.

Eligibility criteria

Qualifiers

Patients with acute coronary syndrome presented to ER of Assiut university hospital scheduled for primary PCI and able to provide informed consent.

Disqualifiers

Patients on previous statin therapy.

Patients with severe renal dysfunction (creatinine clearance <30 mL/min) or other contraindications to PCI.

Patients with missed data or who couldn't be followed up

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

This trial has no locations

Sponsors and collaborators

Assiut University

Lead sponsor

Source ClinicalTrials.gov